Charles A Stiller1, Laura Botta2, David H Brewster3, Vincent K Y Ho4, Anna Maria Frezza5, Jeremy Whelan6, Paolo G Casali7, Annalisa Trama8, Gemma Gatta9. 1. National Cancer Registration and Analysis Service, Public Health England, 4150 Chancellor Court, Oxford OX4 2GX, UK. Electronic address: Charles.stiller@phe.gov.uk. 2. Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: laura.botta@istitutotumori.mi.it. 3. Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. Electronic address: v1dbrews@exseed.ed.ac.uk. 4. Departments of Registry and Research, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, The Netherlands. Electronic address: v.ho@iknl.nl. 5. Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: annamaria.frezza@istitutotumori.mi.it. 6. London Sarcoma Service, University College Hospital, London, UK. Electronic address: Jeremy.whelan@nhs.net. 7. Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: paolo.casali@istitutotumori.mi.it. 8. Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: annalisa.trama@istitutotumori.mi.it. 9. Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: gemma.gatta@istitutotumoti.mi.it.
Abstract
BACKGROUND: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still <60% by 1995-1999. There was large geographical survival variability, mainly for bone tumours, and survival decreased with increasing age at diagnosis. METHODS: Data from 87 population-based cancer registries in 29 countries, extracted from the EUROCARE-5 database, were used to provide updated estimates of survival and describe trends in survival of adults with cancers of these sites across Europe. We calculated 5-year RS for patients diagnosed in 2000-2007. We estimated 5-year RS by the period approach to assess changes in survival between 1999-2001, 2002-2004 and 2005-2007, and provide reliable predictions for recently diagnosed patients. RESULTS: Five-year RS was 60% for adults diagnosed with soft-tissue cancer in 2000-2007 and 53% for those with bone cancer. RS declined with increasing age at diagnosis, especially for bone cancer. Survival from bone cancer varied widely between European regions, from 63 to 62% in Northern and Central Europe to 39% in Eastern Europe. Inter-regional variation was much less for soft-tissue cancer. For both site groupings, there was little evidence of change in five-year RS up to 2002-2004, followed by increases of 3-4% during 2005-2007. CONCLUSIONS: Outcomes for adults with bone and soft-tissue cancer in Europe began to improve around 2005; new therapeutic developments are expected to result in further progress. Survival improvements already achieved must be brought more fully to elderly patients and those in Eastern Europe. European Reference Networks on rare cancers will have a vital role in future progress.
BACKGROUND: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still <60% by 1995-1999. There was large geographical survival variability, mainly for bone tumours, and survival decreased with increasing age at diagnosis. METHODS: Data from 87 population-based cancer registries in 29 countries, extracted from the EUROCARE-5 database, were used to provide updated estimates of survival and describe trends in survival of adults with cancers of these sites across Europe. We calculated 5-year RS for patients diagnosed in 2000-2007. We estimated 5-year RS by the period approach to assess changes in survival between 1999-2001, 2002-2004 and 2005-2007, and provide reliable predictions for recently diagnosed patients. RESULTS: Five-year RS was 60% for adults diagnosed with soft-tissue cancer in 2000-2007 and 53% for those with bone cancer. RS declined with increasing age at diagnosis, especially for bone cancer. Survival from bone cancer varied widely between European regions, from 63 to 62% in Northern and Central Europe to 39% in Eastern Europe. Inter-regional variation was much less for soft-tissue cancer. For both site groupings, there was little evidence of change in five-year RS up to 2002-2004, followed by increases of 3-4% during 2005-2007. CONCLUSIONS: Outcomes for adults with bone and soft-tissue cancer in Europe began to improve around 2005; new therapeutic developments are expected to result in further progress. Survival improvements already achieved must be brought more fully to elderly patients and those in Eastern Europe. European Reference Networks on rare cancers will have a vital role in future progress.
Authors: Konstantin Byrgazov; Claes Anderson; Benjamin Salzer; Eva Bozsaky; Rolf Larsson; Joachim Gullbo; Manfred Lehner; Fredrik Lehmann; Ana Slipicevic; Leo Kager; Mårten Fryknäs; Sabine Taschner-Mandl Journal: Ther Adv Med Oncol Date: 2020-07-29 Impact factor: 5.485
Authors: Bader Alshamsan; Ahmad Badran; Aisha Alshibany; Fatma Maraiki; Mahmoud A Elshenawy; Tusneem Elhassan; Jean Paul Atallah Journal: Cancer Manag Res Date: 2021-08-29 Impact factor: 3.989
Authors: Dide den Hollander; Winette T A Van der Graaf; Marco Fiore; Bernd Kasper; Susanne Singer; Ingrid M E Desar; Olga Husson Journal: ESMO Open Date: 2020-10